191 related articles for article (PubMed ID: 8977174)
1. Allopeptide-specific T cell reactivity altered by peptide analogs.
Colovai AI; Liu Z; Harris PE; Cortesini R; Suciu-Foca N
J Immunol; 1997 Jan; 158(1):48-54. PubMed ID: 8977174
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic core amino acids of an immunodominant allopeptide are important for MHC binding and TCR recognition.
Sitaru AG; Timmermann W; Ulrichs K; Otto C
Hum Immunol; 2004 Aug; 65(8):817-25. PubMed ID: 15336783
[TBL] [Abstract][Full Text] [Related]
3. T cell recognition of allopeptides in context of syngeneic MHC.
Liu Z; Braunstein NS; Suciu-Foca N
J Immunol; 1992 Jan; 148(1):35-40. PubMed ID: 1530797
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides.
Geluk A; Van Meijgaarden KE; Janson AA; Drijfhout JW; Meloen RH; De Vries RR; Ottenhoff TH
J Immunol; 1992 Nov; 149(9):2864-71. PubMed ID: 1383331
[TBL] [Abstract][Full Text] [Related]
5. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues.
Ostrov D; Krieger J; Sidney J; Sette A; Concannon P
J Immunol; 1993 May; 150(10):4277-83. PubMed ID: 8482836
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR peptide-induced alloreactive T cell lines reveal an HLA-DR sequence that can be both "dominant" and "cryptic": evidence for allele-specific processing.
de Koster HS; van Rood JJ; Termijtelen A
Eur J Immunol; 1992 Jun; 22(6):1531-9. PubMed ID: 1376262
[TBL] [Abstract][Full Text] [Related]
7. Characterization of HLA-DR- and TCR-binding residues of an immunodominant and genetically permissive peptide of the 16-kDa protein of Mycobacterium tuberculosis.
Caccamo N; Meraviglia S; La Mendola C; Bosze S; Hudecz F; Ivanyi J; Dieli F; Salerno A
Eur J Immunol; 2004 Aug; 34(8):2220-9. PubMed ID: 15259019
[TBL] [Abstract][Full Text] [Related]
8. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
[TBL] [Abstract][Full Text] [Related]
9. Analysis of peptide residues interacting with MHC molecule or T cell receptor. Can a peptide bind in more than one way to the same MHC molecule?
Kurata A; Berzofsky JA
J Immunol; 1990 Jun; 144(12):4526-35. PubMed ID: 2141038
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
Li X; Li R; Li Z
Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
[TBL] [Abstract][Full Text] [Related]
11. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320.
Zeliszewski D; Golvano JJ; Gaudebout P; Dorval I; Freidel C; Gebuhrer L; Betuel H; Borras-Cuesta F; Sterkers G
J Immunol; 1993 Dec; 151(11):6237-47. PubMed ID: 7504016
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of allorecognition of major histocompatibility complex molecules by T lymphocytes.
Lombardi G; Lechler R
Ann Ist Super Sanita; 1991; 27(1):7-14. PubMed ID: 1958030
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR.
Doherty DG; Penzotti JE; Koelle DM; Kwok WW; Lybrand TP; Masewicz S; Nepom GT
J Immunol; 1998 Oct; 161(7):3527-35. PubMed ID: 9759873
[TBL] [Abstract][Full Text] [Related]
14. Modification of peptide interaction with MHC creates TCR partial agonists.
Ryan KR; McNeil LK; Dao C; Jensen PE; Evavold BD
Cell Immunol; 2004 Jan; 227(1):70-8. PubMed ID: 15051516
[TBL] [Abstract][Full Text] [Related]
15. MHC class II binding of peptides derived from HLA-DR 1.
Harris PE; Liu Z; Suciu-Foca N
J Immunol; 1992 Apr; 148(7):2169-74. PubMed ID: 1545124
[TBL] [Abstract][Full Text] [Related]
16. Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity.
Frasca L; Tamir A; Jurcevic S; Marinari B; Monizio A; Sorrentino R; Carbonari M; Piccolella E; Lechler RI; Lombardi G
Transplantation; 2000 Aug; 70(4):631-40. PubMed ID: 10972222
[TBL] [Abstract][Full Text] [Related]
17. Limited usage of T cell receptor V beta genes by allopeptide-specific T cells.
Liu Z; Sun YK; Xi YP; Hong B; Harris PE; Reed EF; Suciu-Foca N
J Immunol; 1993 Apr; 150(8 Pt 1):3180-6. PubMed ID: 8468463
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
Cheng YJ; Zhou Q; Li ZG
Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
[TBL] [Abstract][Full Text] [Related]
19. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes.
Geluk A; van Meijgaarden KE; Roep BO; Ottenhoff TH
J Autoimmun; 1998 Aug; 11(4):353-61. PubMed ID: 9776713
[TBL] [Abstract][Full Text] [Related]
20. Characterization of T cell epitopes restricted by HLA-DP9 in streptococcal M12 protein.
Dong RP; Kamikawaji N; Toida N; Fujita Y; Kimura A; Sasazuki T
J Immunol; 1995 May; 154(9):4536-45. PubMed ID: 7536773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
